Halozyme Therapeutics Profit Margin

The latest profit margin for HALO is 24.86% as of June 2026. That compares with 47.28% in the prior-year period — down 47.4% year over year. That is above the Healthcare sector average of 13.71%. Investors often review this figure alongside Halozyme Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HALO's profit margin moved from 47.28% to 24.86% — a 47.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Halozyme Therapeutics's valuation or profitability profile.

Against Healthcare companies, HALO currently prints 24.86% for profit margin, while the sector average sits near 13.71%. That is roughly 81.3% above the sector mean. Large gaps often invite a closer look at Halozyme Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Halozyme Therapeutics converts resources into returns. At 24.86%, HALO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 47.28% in the prior-year period — down 47.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HALO's profit margin (24.86%), review year-over-year change from 47.28%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.